Annals of Surgical Oncology

, Volume 20, Issue 1, pp 295–304 | Cite as

Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival

  • Sulaiman Nanji
  • Sean Cleary
  • Paul Ryan
  • Maha Guindi
  • Subani Selvarajah
  • Paul Grieg
  • Ian McGilvary
  • Bryce Taylor
  • Alice Wei
  • Carol-Anne Moulton
  • Steven Gallinger
Hepatobiliary Tumors



Hepatic metastasis from colorectal cancer (CRC) is best managed with a multimodal approach; however, the optimal timing of liver resection in relation to administration of perioperative chemotherapy remains unclear. Our strategy has been to offer up-front liver resection for patients with resectable hepatic metastases, followed by post–liver resection chemotherapy. We report the outcomes of patients based on this surgical approach.


A retrospective review of all patients undergoing liver resection for CRC metastases over a 5-year period (2002–2007) was performed. Associations between clinicopathologic factors and survival were evaluated by the Cox proportional hazard method.


A total of 320 patients underwent 336 liver resections. Median follow-up was 40 (range 8–80) months. The majority (n = 195, 60.9 %) had metachronous disease, and most patients (n = 286, 85 %) had a major hepatectomy (>3 segments). Thirty-six patients (11 %) received preoperative chemotherapy, predominantly for downstaging unresectable disease. Ninety-day mortality was 2.1 %, and perioperative morbidity occurred in 68 patients (20.2 %). Actual disease-free survival at 3 and 5 years was 46.2 % and 42 %, respectively. Actual overall survival (OS) at 3 and 5 years was 63.7 % and 55 %, respectively. Multivariate analysis identified four factors that were independently associated with differences in OS (hazard ratio; 95 % confidence interval): size of metastasis >6 cm (2.2; 1.3–3.5), positive lymph node status of the primary CRC (N1 (2.0; 1.0–3.8), N2 (2.4; 1.2–4.9)), synchronous disease (2.1; 1.3–3.5), and treatment with chemotherapy after liver resection (0.42; 0.23–0.75).


Up-front surgery for patients with resectable CRC liver metastases, followed by chemotherapy, can lead to favorable OS.


  1. 1.
    Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989;210:127–38.PubMedCrossRefGoogle Scholar
  2. 2.
    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.PubMedCrossRefGoogle Scholar
  4. 4.
    de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–8.PubMedGoogle Scholar
  5. 5.
    Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22.PubMedCrossRefGoogle Scholar
  6. 6.
    House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744–52, 752–5.Google Scholar
  7. 7.
    Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–88.PubMedCrossRefGoogle Scholar
  8. 8.
    Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Zalinski S, Abdalla EK, Mahvash A, et al. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol. 2009;16:1208–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Vauthey JN, Nordlinger B, Kopetz S, et al. Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: a debate over goals of research and an approach while the jury remains out. Ann Surg Oncol. 2010;17:1983–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Cobourn CS, Makowka L, Langer B, et al. Examination of patient selection and outcome for hepatic resection for metastatic disease. Surg Gynecol Obstet. 1987;165:239–46.PubMedGoogle Scholar
  18. 18.
    Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat. 1958;53:457–81.CrossRefGoogle Scholar
  19. 19.
    Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCrossRefGoogle Scholar
  22. 22.
    Figueras J, Valls C, Rafecas A, et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14:1151–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Langer B, Bleiberg H, Labianca R. Fluorouracil (FU) plus I-leukovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial (abstract). Proc Am Soc Clin Oncol. 2002;21(Suppl):592.Google Scholar
  30. 30.
    Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Sulaiman Nanji
    • 1
  • Sean Cleary
    • 2
  • Paul Ryan
    • 3
  • Maha Guindi
    • 4
  • Subani Selvarajah
    • 2
  • Paul Grieg
    • 2
  • Ian McGilvary
    • 2
  • Bryce Taylor
    • 2
  • Alice Wei
    • 2
  • Carol-Anne Moulton
    • 2
  • Steven Gallinger
    • 2
  1. 1.Department of SurgeryQueen’s UniversityKingstonCanada
  2. 2.Department of SurgeryUniversity Health Network, University of TorontoTorontoCanada
  3. 3.Department of PathologyUniversity of TorontoTorontoCanada
  4. 4.Department of Pathology and Laboratory MedicineCedars-Sinai Medical CentreLos AngelesCanada

Personalised recommendations